Zymeworks (ZYME) Posts Revs of $1.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- BofA lifts targets on AMD and ARM, raises CPU TAM to $170bn
Zymeworks Reports Second Quarter 2017 Financial Results
August 8, 2017 4:01 PM EDTVANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Zymeworks) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the second quarter ended June 30, 2017.
During the second quarter, in addition to the completion of our initial public offering, we made significant progress on our clinical and partnered programs, said Ali Tehrani, Ph.D., Zymeworks President & CEO. We presented detailed dose escalation data at ASCO demonstrating safety and anti-tumor activity for ZW25. We also announced progress... More
